Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 26, 2026Clinical and Experimental MedicineOpen Access

TMEM132A is associated with metabolic reprogramming, macrophage-oriented immune remodeling, and breast cancer progression

View Full Paper
Ask AI
Bookmark
Share

Authors

YCYa ChenRLRuonan LinJPJinghao Pan

Discussion

Loading...

Member takes

Overview

Evaluating TMEM132A identifies adverse outcomes in breast cancer while highlighting immune interactions.

Key Points

  • The research aims to investigate TMEM132A's role as a biomarker linking breast cancer progression with metabolic and immune changes.
  • Analyzed bulk cohorts from multiple databases including The Cancer Genome Atlas and Gene Expression Omnibus.
  • Conducted single cell RNA sequencing and spatial transcriptomics for localization of TMEM132A.
  • Employed cell communication inference with correlation-based validation and differential expression analyses like GSEA and GSVA.
  • TMEM132A was consistently upregulated in breast tumors compared to normal tissue across datasets.
  • High TMEM132A expression correlated with poorer patient outcomes and advanced clinical categories.
  • Localization studies showed TMEM132A predominantly in malignant epithelial cells and associated with macrophage features.

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/69c4cc75fdc3bde448917c7bhttps://doi.org/10.1007/s10238-026-02125-3
View Full Paper
Ask AI
Bookmark
Share